Our very own Richard Little, who was born in Fort Williams, Scotland, was recently highlighted in this article from The Highland Times talking about the progress Exsurgo has made so far with Axon and their UK trials.
As the article said:
A recent UK study has confirmed the exciting potential of a breakthrough treatment for chronic pain management developed by neuroscience company, Exsurgo.
Chronic pain (defined as pain that persists for longer than three months) affects up to 1 in 5 people around the world and is a massive burden on healthcare systems and economies.
Approximately 8 million adults in the UK report chronic pain that is moderate to severely disabling, with back pain alone costing the UK economy £10 billion a year.
Exsurgo’s “Axon” system uses EEG (electroencephalography) neurofeedback to train chronic pain sufferers to manage their pain – and avoid or reduce the use of pharmaceutical drugs that bring risks of addiction or side effects.
In the UK study, conducted from mid 2020 until early 2021, patients reported significant reductions in their levels of pain, anxiety and depression.
At the same time, they reported improvements in sleep, mood and quality of life.
Furthermore, the improvements from the eight weeks of neurofeedback training were sustained at follow up points – 4, 12 and 26 weeks.
The article continues:
Exsurgo CEO Richard Little said the positive UK trial results were the next important step in the company’s ongoing five-year journey to develop, validate and then commercialise its neuroscience technologies.
“As we’d hoped, this trial shows us that we have a solution that can change lives and makes EEG neurofeedback therapy much more affordable and accessible.”
If you’d like to read, the full article can be accessed in the link above.